CyFlow CD19 Biotin
| 品番 | AA490134 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD19 BIOTIN,LT19 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 Biotin (AQ807476) |
||
| 反応性|交差吸着 | Human | レーザー | |
| 抗原 | CD19, B4 | 最大蛍光波長 | - |
| クローン | LT19 | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Biotin |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD19 BIOTIN,LT19
特異性
The mouse monoclonal antibody LT19 recognizes CD19 antigen, a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells.
抗原情報
CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
利用方法
The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working usage is 5 µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine‑guanosine‑independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J·Immunol. 2003·Oct·1; 171(7):3697‑704. <·PMID:·14500668·>
• Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src‑family protein tyrosine kinase activation. J·Immunol. 1999·Jun·15; 162(12):7088‑94. <·PMID:·10358152·>
• Inabe K, Kurosaki T: Tyrosine phosphorylation of B‑cell adaptor for phosphoinositide 3‑kinase is required for Akt activation in response to CD19 engagement. Blood. 2002·Jan·15; 99(2):584‑9. <·PMID:·11781242·>
• Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005·Nov·15; 106(10):3567‑74. <·PMID:·16046525·>
• Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1‑induced humoral autoimmunity but not clinical nephritis. Arthritis·Rheum. 2007·Sep; 56(9):3057‑69. <·PMID:·17763445·>
• Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8‑color flow cytometry protocol in routine hematological practice. Int·J·Lab·Hematol. 2014·Apr; 36(2):165‑71. <·PMID:·24028768·>
• van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody‑deficiency syndrome due to mutations in the CD19 gene. N·Engl·J·Med. 2006·May·4; 354(18):1901‑12. <·PMID:·16672701·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN